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Abstract We investigated if the MET-activating point
mutation Y1253D influences clinical outcomes in patients
with advanced squamous cell carcinoma of the head and
neck (HNSCC). The study population consisted of 152
HNSCC patients treated by hyperfractionated radiotherapy
alone or concomitant with chemotherapy between Septem-
ber 1994 and July 2000. Tumors were screened for the
presence of the MET-activating point mutation Y1253D.
Seventy-eight patients (51%) received radiotherapy alone,
74 patients (49%) underwent radiotherapy concomitant with
chemotherapy. Median patient age was 54 years and median
follow-up was 5.5 years. Distant metastasis-free survival,
local relapse-free survival and overall survival were com-
pared with MET Y1253D status. During follow-up, 29
(19%) patients developed distant metastasis. MET Y1253D
was detected in tumors of 21 out of 152 patients (14%).
Distant metastasis-free survival (P = 0.008) was associated
with MET Y1253D. In a multivariate Cox regression
model, adjusted for T-category, only presence of MET
Y1253D was associated with decreased distant metastasis-
free survival: hazard ratio = 2.5 (95% confidence interval:
1.1, 5.8). The observed association between MET Y1253D-
activating point mutation and decreased distant metastasis-
free survival in advanced HNSCC suggests that MET may be
a potential target for specific treatment interventions.
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Abbreviations
SAKK CC Swiss Group for Clinical Cancer Research
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HNSCC Squamous cell carcinoma of the head and
neck
EGFR Epidermal growth factor receptor
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DMFS Distant metastasis-free survival
LRFS Local relapse-free survival
OS Overall survival
RCT Radiochemotherapy
RT Radiotherapy
PCR Polymerase chain reaction
PNA Peptide nucleic acid
SAS Statistical analysis systems
CI Confidence interval
HR Hazard ratio
Introduction
Development of distant metastasis has a crucial impact on
therapy and prognosis of advanced squamous cell
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carcinomas of the head and neck (HNSCC). If metastatic
disease occurs, overall survival is significantly decreased
[1]. During the last decade the incidence of local relapse
[2] and distant metastasis [3, 4] was significantly reduced
by the establishment of either postoperative or definitive
concomitant radiochemotherapy, leading to an increase in
overall survival [4–8]. However, the development of local
and/or systemic tumor relapse is still considerable and
remains to be further improved. An increasing body of
evidence points towards the impact of various growth
factor signaling pathways in the oncogenesis and prognosis
of HNSCC, representing attractive anti-neoplastic targets
[9–11]. Compelling evidence from both experimental and
translational studies on the impact of the epidermal growth
factor receptor (EGFR) signalling in prognosis and treat-
ment failure of HNSCC led recently to the successful
introduction of cetuximab, a monoclonal anti-EGFR anti-
body [12]. MET, the tyrosine kinase receptor for hepato-
cyte growth factor/scatter factor (HGF/SF) is involved in
carcinogenesis, tumor progression and promotes aggressive
cellular invasiveness which is strongly associated with tumor
metastasis [13–15]. MET is not only involved in onset but
also in maintenance of experimental metastasis [16]. Due to
its extensive involvement in cancer development and its
expression in various human cancers [17], MET has been
identified as an attractive anti-cancer target against which
numerous inhibitors have been developed, some of them
being currently tested in clinical trials. Aberrant MET sig-
naling can either be achieved by autocrine or paracrine HGF/
SF signaling, gene overexpression or point mutations leading
to constitutive kinase activity, or by gene amplification or
rearrangement. The detection of point mutations is chal-
lenged by the fact that clinical specimens often contain only a
small number of tumor cells within a large background of
normal tissue and that somatic point mutations are some-
times present only in a subset of the tumor cells. However,
the detection of low-abundance mutations is important since
clonal expansion of these cells can lead to a more aggressive
tumor phenotype and patients with MET mutations might
differentially benefit from MET targeted therapy [18].
The MET Y1253D activating point mutation was first
identified in HNSCC [19] and we have later described its
prevalence and clinical impact in a retrospective cohort of
radiotherapy-treated patients with oropharyngeal cancer
[20]. MET Y1253D has also been shown to couple and
activate signalling pathways, which confer a motile-inva-
sive phenotype on cancer cells [21]. As a next step, the
current study was conducted to determine in a prospective
setting if the MET Y1253D mutation is associated with
distant metastasis-free survival (DMFS), local relapse-free
survival (LRFS) or overall survival (OS) in advanced
HNSCC.
Materials and methods
Patients and clinical protocol
Pre-therapy tumor samples were analyzed from patients who
were treated in a multicenter phase III trial (SAKK 10/94)
investigating the use of two courses of cisplatin simulta-
neously with hyperfractionated radiotherapy (RCT) com-
pared to radiotherapy (RT) alone [22]. The protocol for
SAKK 10/94 was approved by local ethics review boards and
all patients gave informed consent. The trial was registered at
the National Institute of Health (www.clinicaltrial.gov;
identifier number: NCT00002654).
Tissue from 152 of the 224 patients enrolled in the trial
were available for analysis. Tumor material for the
remaining 72 patients could not be collected from the
pathology departments of the participating centres. Inclu-
sion and exclusion criteria of the trial have been previously
described [22]. Briefly, all eligible patients had invasive
squamous cell carcinoma of the oral cavity, oro- or hypo-
pharynx, or larynx at different clinical stages. Those with
primary tumor sites in the nasopharynx or paranasal sinuses
were excluded from the trial. Tumors were classified
according to the tumor-node-metastasis staging system
(International Union Against Cancer, edition 4, 1987).
Each eligible participant underwent clinical evaluation by a
multidisciplinary team. This evaluation included a chest
radiograph, computed tomography of the head and neck,
and examination of the upper aerodigestive tract under
general anesthesia. The judgement of operability was left
to the treating surgeon. To identify and exclude patients
with distant metastases, liver ultrasound or abdominal
computed tomography and bone scintigraphy were man-
datory for all patients with hypopharynx cancer and/or
positive lower neck nodes. With the exception of those
having basal cell carcinoma of the skin, squamous cell
carcinoma of the lip, or in situ carcinoma of the uterine
cervix, all patients with prior malignancies were excluded
from the trial. All patients were seen by head and neck
specialists weekly if C grade 3 mucositis occurred, and
otherwise at 6 weeks after completion of trial therapy,
every 2 months during the first year, every 3 months dur-
ing the second year and every 6 months thereafter until
death.
Radiotherapy and chemotherapy
Delivery of treatment has been described previously [22].
All 152 patients analyzed were treated with radiotherapy
up to a median total dose of 74.4 Gy (72–76.8 Gy), during
7 weeks, with 1.2 Gy given twice daily with an interfrac-
tion interval of 6 h.
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Cisplatin 20 mg/m2 was administered with intravenous
hydration on 5 consecutive days during weeks 1 and 5 or 6
of radiotherapy, 1.5 h before the afternoon radiotherapy
session. A total of 71/74 (96%) patients received at least
1 cycle of cisplatin and 55/74 (74%) patients received a
total of 2 cycles.
DNA extraction and genotyping
All the pre-therapeutic formalin fixed biopsies were
reviewed by the local pathologist to assure the presence of
squamous cell cancer in the paraffin blocks. DNA was
extracted from 10 mm sections of paraffin blocks as pre-
viously described [23]. The DNA samples were screened
for MET Y1253D using real-time polymerase chain
reaction (PCR) along with peptide nucleic acid (PNA)-
based DNA clamping and melting curve analysis as previ-
ously described [20]. Briefly, amplified MET wild-type and
mutated MET Y1253D were distinguished using melting
curve analysis. Addition of the PNA to the reaction mixture
allowed detection of the presence of MET Y1253D muta-
tion within a background of at least 98% wild type plasmid.
154 bp fragment corresponding to MET exon 19, where
Y1253D is located, was amplified and analyzed by running
a melting curve. The amplification primers were MET 9 19
F: 50- ATTCACAGTCAAGGTTGCTGATT and MET 9
19 R: 50- CTTACCACATCTGACTTGGTGGTA. A pair of
hybridization probes were used for the detection of the
amplified PCR product. The anchor probe was 30-terminal
blocked against extension (phosphate) and contained a 50-
terminal LightCycler Red-640 label: LC640-TCATACA
TGTCTCTGGCAAGACCA-PH. The sensor probe that was
designed to fully match the allele that harbours the T3757G
substitution was 30-terminally labelled with fluorescein: 50-
GTTGTGTACACTATCGTATTCTTT-F (mutated base is
underlined). The wild-type-specific PNA oligomer 50-TA
CACTATAGTATTCTTT was present (9 lM) to suppress
the amplification of the wild-type allele. Real-time PCR
was performed with a LightCycler (Roche Diagnostics)
using FastStart DNA reagents (Roche). PCR was performed
as follows: 1 cycle for 10 min at 95C (enzyme activation),
65 cycles with 10 s at 95C (denaturation) and 40 s at 57C
(annealing of amplification primers and hybridization
probes, elongation). Melting analysis was performed by
30 s heating at 95C, 150 s incubation at 40C and slowly
heating (0.1C/s) from 40 to 70C and subsequent fluores-
cence monitoring. Results were processed using the Light-
Cycler software package (Version 3.5.28).
Statistical analysis
The primary endpoint was development of distant metas-
tasis. Other endpoints of interest were LRFS and OS. All
time-to-event end points were read as the time from the
trial registration until either a positive distant metastasis
result for DMFS, local tumor progression after incomplete
remission and/or local relapse after complete remission for
LRFS, or death for OS. For calculation of the median
follow-up all patients were used, with the patients who died
being censored at the time of death. Patients not reaching
an event were censored at the time they were last known to
be alive. Continuous baseline variables were dichotomized
as follows; age (\54 vs. C54 years), T-category (T1/2/3 vs.
T4), N-category (N0/1 vs. N2/3) and disease site (oropharynx
vs. other). T-categories were grouped to achieve an equal
number of events in both sets of patients. The association
between all baseline variables and MET Y1253D status
were assessed using the Chi-squared or Fisher0s exact test.
Cox regression analysis was performed to determine if
MET Y1253D status is an independent risk factor for
either DMFS, LRFS or OS at both the univariate and mul-
tivariate level. Inclusion criteria for covariates and con-
founders to be entered into the multivariate analysis was a
P-value \ 0.1 in the univariate analysis. The final model
contained the primary variables of interest (MET Y1253D
status), variables to be considered of high clinical interest
regardless of statistical significance and also variables with
a statistical significance level of 5% or less. If chemo-
therapy administration was not found to be statistically
significant in the model as an explanatory variable it was
then included as a stratification variable. All analyses were
carried out using the Statistical Analysis Systems (SAS)
package (SAS Institute, Cary, NC, USA, version 9.1).
Results
Patient characteristics and MET genotyping
Patient characteristics are summarized in Table 1. Median
patient age was 54 years (range 49–63 years). Median fol-
low-up time was 5.5 years (range 0.1–12.1 years). The
follow-up was less than 3 months in three patients, the
follow-up was less than 6 months in 10 patients. Ten (7%)
patients had a tumor of the oral cavity, 78 (51%) of the
oropharynx, 40 (26%) of the hypopharynx and 24 (16%) of
the larynx. MET Y1253D was found in 21 patients (preva-
lence of 14%), all of whom were male. MET Y1253D
status was associated with male gender (P = 0.045) and
advanced T-category (P = 0.016), but not with N-category
or age (P = 0.877 and 0.130, respectively). MET Y1253D
was not associated with T-category when T1 and T2
tumors were compared with T3 and T4 tumors (data not
shown). MET Y1253D was also not associated with
N-category when node negative patients were compared
with node positive patients (N0 vs. N1/2/3; data not shown).
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Smoking status, alcohol consumption and tumor differen-
tiation were not available from the study records and thus
comparison with MET Y1253D status could not be
performed.
MET Y1253D genotype and DMFS
A total of 29 out of 152 (19%) HNSCC patients developed
distant metastasis after the initial therapy, all occurring
within 5 years from trial registration. Distant metastasis
were observed at various sites with, by far the most com-
mon sites being bone, lung and pleura. Among the
29 patients 28% (8/29) belonged to the MET Y1253D
positive group. The 5-year DMFS probability was 72.96%
(95% confidence interval (CI): 62.68, 80.83). As shown by
Kaplan–Meier plot (Fig. 1a), the 5-year DMFS rates were
77.28% (95% CI: 66.48, 84.98) for those negative for MET
Y1253D, and 44.13% (95% CI: 16.08, 69.34) for those
positive for MET Y1253D (hazard ratio (HR): 3.016
(95% CI: 1.332, 6.832); log-rank P = 0.005).
Twenty-six patients underwent salvage surgery (3 were
MET Y1253D positive, 23 were MET Y1253D negative).
Of these, only one MET Y1253D negative patient devel-
oped distant metastasis.
Table 1 Patient baseline characteristics
Parameter Total (%) MET Y1253D (%) P-value
Negative Positive
Number of patients 152 (100) 131 (86) 21 (14)
Sex
Male 130 (86) 109 (83) 21 (100) 0.045
Female 22 (14) 22 (17) 0
Age (years)
\54 74 (49) 67 (51) 7 (33) 0.130
C54 78 (51) 64 (49) 14 (67)
T-category
T1/2/3 94 (62) 86 (66) 8 (38) 0.016
T4 58 (38) 45 (34) 13 (62)
N-category
N0/1 70 (46) 60 (46) 10 (48) 0.877
N2/3 82 (54) 71 (54) 11 (52)
Disease site
Oropharynx 78 (51) 65 (50) 13 (62) 0.538
Other 74 (49) 66 (50) 8 (38)
Chemotherapy
No 78 (51) 71 (54) 7 (33) 0.334
Yes 74 (49) 60 (46) 14 (67)
Tumors were classified according to the tumor-node-metastasis
staging system (International Union Against Cancer, edition 4, 1987)
Fig. 1 Actuarial analysis of 5 year a distant metastasis-free survival,
b local relapse-free survival and c overall survival with the patients
being stratified according to their MET Y1253D status
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In the univariate analysis, advanced T-category was also
found to be associated with a statistically significant HR:
2.452 (95% CI: 1.179, 5.101) (P = 0.016).
In the multivariate analysis using the Cox regression
model adjusted for T-category and stratified by chemo-
therapy administration, MET Y1253D was independently
associated with decreased DMFS, HR 2.487 (95% CI:
1.062, 5.822) (P = 0.036) (Table 2).
MET Y1253D genotype and LRFS
Among the 152 HNSCC patients, 48 (32%) developed a
local relapse after completion of therapy. The Kaplan–
Meier plots showed no significant difference in patients
LRFS according to MET Y1253D status, log rank
P = 0.764 (Fig. 1b). Decreased LRFS was associated with
female gender (HR: 2.099 (95% CI: 1.070, 4.119)
(P = 0.031)), advanced T-category (HR: 2.040 (95% CI:
1.157, 3.598) (P = 0.014)) and absence of chemotherapy
administration (HR: 0.406 (95% CI: 0.218, 0.757)
(P = 0.005)) at a univariate level. In the multivariate Cox
regression model both the T-category and chemotherapy
administration were associated with LRFS (Table 2).
MET Y1253D genotype and OS
Ninety-five out of 152 (62.5%) HNSCC patients died
during the follow-up with a median OS time of 3.35 years
(95% CI: 2.06, 4.59). OS was not significantly different
according to the MET Y1253D status, log rank P = 0.363
(Fig. 1c) however, OS was associated with advanced
T-category (HR: 1.886 (95% CI: 1.254, 2.838) (P =
0.002)). The Cox regression model in the multivariate
analysis produced similar results for the T-category when
stratified for chemotherapy administration (Table 2).
At the time of death, of the MET Y1253D negative
patients 24 had local relapse only, 11 had distant metastasis
only and 9 had both local relapse and distant metastasis.
For the MET Y1253D positive patients 3 had local relapse
only, 3 had distant metastasis only and 3 had both local
relapse and distant metastasis.
Discussion
Our data indicate that MET Y1235D point mutation is
an independent genetic risk factor for the development of
distant metastasis after completion of definitive radiation
therapy in advanced HNSCC patients. These results have
been obtained by correlation of MET Y1235D occurrence
and disease outcome within a cohort of patients from a
prospective randomized trial of 152 HNSCC patients with
a median follow-up of 5.5 years. We had previously
described a MET Y1253D prevalence of 10.9% in a ret-
rospective cohort of 138 HNSCC patients of whom all had
tumors of the oropharynx and of whom 77% were treated
by RT alone and 23% by combined RCT with a median
follow-up of the surviving patients of 2.6 years [20]. In this
former study there was an association between MET
Y1253D and distant metastasis (HR: 2.41), which, how-
ever, did not reach statistical significance. In line with the
retrospective results, the current study revealed a similar
prevalence of MET Y1253D (14%) with a comparable
hazard ratio (3.016) for DMFS, now reaching statistical
significance and strengthening the assumption that the
impact of MET Y1253D on the development of distant
metastasis in advanced HNSCC is real. While the retro-
spective study showed a significant association between the
presence of MET Y1253D and local failure, the current
analysis failed to confirm this finding. The absence of an
Table 2 Treatment outcome analysis following radical radiotherapy ± chemotherapy of HNSCC
Factor Cox regression analysis [hazard ratio (95% confidence interval) (P-value)]
DMFS* LRFS Overall survival*
Univariate analysis
Sex: female 0.956 (0.333, 2.749) (0.934) 2.099 (1.070, 4.119) (0.031) 0.932 (0.508, 1.710) (0.820)
Age (years): C54 1.057 (0.508, 2.200) (0.882) 0.604 (0.340, 1.072) (0.085) 0.847 (0.566, 1.267) (0.419)
T-category: T4 2.452 (1.179, 5.101) (0.016) 2.040 (1.157, 3.598) (0.014) 1.886 (1.254, 2.838) (0.002)
N-category: N2/3 1.624 (0.767, 3.440) (0.206) 1.000 (0.568, 1.763) (0.999) 1.171 (0.782, 1.754) (0.444)
Chemotherapy: yes 0.702 (0.334, 1.474) (0.350) 0.406 (0.218, 0.757) (0.005) 0.711 (0.471, 1.074) (0.105)
MET Y1253D: positive 3.016 (1.332, 6.832) (0.008) 1.130 (0.507, 2.520) (0.766) 1.303 (0.736, 2.306) (0.364)
Multivariate analysis
MET Y1253D: positive 2.487 (1.062, 5.822) (0.036) 0.894 (0.389, 2.053) (0.791) 1.203 (0.670, 2.160) (0.535)
T-category: T4 2.117 (0.987, 4.539) (0.054) 2.023 (1.122, 3.647) (0.019) 1.924 (1.266, 2.925) (0.002)
Chemo: yes 0.416 (0.223, 0.775) (0.006)
* Stratified by chemotherapy administration in the multivariate analysis
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association between LRFS and MET Y1253D status
may be caused by differences in the study populations i.e.,
treatment site, treatment and follow-up (in the context of
comparison of a retrospective and prospective trial). To
adjust for some of these imbalances we performed a sub-
group analysis in oropharynx patients (78/152) but
again there was no association between LRFS and MET
Y1253D found (data not shown). Since the median follow-
up of the retrospective study was 2.6 years, we calculated
for the current study also the 3-year actuarial DMFS, LRFS
and OS rates which, however, revealed comparable results
to the 5-year data.
The fact that there was no female patient with a MET
Y1253D point mutation could possibly be attributed to a
different mechanism of cancer development as it has been
stated by us and others [23, 24]. One limitation of our study
is the fact that the MET Y1253D mutation was only
found in 14% of the patients and distant metastasis
occurred only in 19%. This limits the statistical signifi-
cance of our results. Another limitation is the lack of
prospective stratification according to the MET Y1253D
status within the prospective study, thus the incidence of
the mutation in the treatment group was different
(Table 1). Further, metastatic tissue was not available for
analysis, thus the MET Y1253D status was only assessed
in primary tumors. It would be highly desirable indeed to
analyse metastases for the presence of mutations; however,
there is a very high barrier from ethical committees to
submit patients for invasive procedures such as removal of
tumor tissue for scientific reasons without direct clinical
implications. However, it has been shown by others that the
incidence of MET Y1253D is higher in metastatic tissue
as compared to the corresponding primary tumors which
suggests that cells expressing mutant MET undergo clonal
expansion during HNSCC progression [19].
Despite significant improvement in local tumor control,
distant metastasis-free survival and overall survival in head
and neck cancers during the last years, the development of
distant metastasis is still a major clinical problem and the
development of new therapeutic strategies is therefore of
great interest. Previous studies have associated both MET
receptor expression as well as somatic mutations of the
MET oncogene with invasive growth and distant metastasis
[13–15]. MET signaling can be inhibited by various
approaches, including inhibition of ligand-receptor inter-
action, inhibition of tyrosine kinase catalytic activity and
inhibition of receptor-effector interactions [16, 18, 25, 26].
Various MET inhibitors are currently undergoing develop-
ment in phase I to II studies in cancer. The association
between MET Y1253D status and DMFS strongly points
towards a potential role for MET inhibitors as a novel
specific treatment strategy to reduce the risk of distant
metastasis in patients with advanced head and neck cancers.
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